KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Working Capital Changes (2023 - 2025)

Biocryst Pharmaceuticals' Other Working Capital Changes history spans 9 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 39.86% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $7.8 million, changed N/A, while the annual FY2025 figure was $7.8 million, N/A changed from the prior year.
  • Other Working Capital Changes reached $1.9 million in Q4 2025 per BCRX's latest filing, down from $5.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.9 million in Q3 2025 to a low of -$2.3 million in Q3 2023.
  • Average Other Working Capital Changes over 3 years is $549750.0, with a median of $48500.0 recorded in 2023.
  • The largest YoY upside for Other Working Capital Changes was 430.55% in 2024 against a maximum downside of 3060.0% in 2024.
  • A 3-year view of Other Working Capital Changes shows it stood at -$419000.0 in 2023, then soared by 430.55% to $1.4 million in 2024, then skyrocketed by 39.86% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Other Working Capital Changes are $1.9 million (Q4 2025), $5.9 million (Q3 2025), and -$160000.0 (Q2 2025).